Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients

Resistance to drug treatments is common in prostate cancer (PCa), and the gain-of-function mutations in human androgen receptor (AR) represent one of the most dominant drivers of progression to resistance to AR pathway inhibitors (ARPI). Previously, we evaluated the in vitro response of 24 AR mutati...

Full description

Bibliographic Details
Main Authors: Nada Lallous, Oliver Snow, Christophe Sanchez, Ana Karla Parra Nuñez, Bei Sun, Ahmed Hussain, Joseph Lee, Helene Morin, Eric Leblanc, Martin E. Gleave, Artem Cherkasov
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
androgen receptor
antagonists
castration-resistant prostate cancer (CRPC)
darolutamide
drug resistance
mutations
Online Access:https://www.mdpi.com/2072-6694/13/12/2939

Internet

https://www.mdpi.com/2072-6694/13/12/2939

Similar Items